

**Date: 11.11.2025**

To,  
**BSE Limited**  
The Compliance Department of Corporate Services,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001.

**Scrip Code: 531592**

**Subject: Submission of Clear Copy of Financial Results for the quarter and half year ended September 30, 2025.**

Dear Sir/Madam,

With respect to your email dated 11<sup>th</sup> November, 2025 regarding Results document/ Figures are Not Clear in pdf submitted for the quarter and half year ended September 30, 2025, In this regard, we are enclosing herewith a clear copy of the aforesaid financial results together with Limited Review Reports.

Kindly take the same on records for your perusal.

Thanking you,

Yours faithfully,

**For Genpharmasec Limited**

SOHAN  
CHATURVEDI

Digitally signed by  
SOHAN CHATURVEDI  
Date: 2025.11.11  
15:37:10 +05'30'



**Mr. Sohan Chaturvedi**  
**Whole time director & CFO**  
**DIN- 09629728**

**Encl: A/a**

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited  
Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing  
Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To,  
The Board of Directors of Genpharmasec Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of Genpharmasec Limited ('the Company') for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.


**Other Matter**

5. The review of standalone unaudited quarterly financial results for the period ended June 30, 2025, included in the Statement was carried out and reported by erstwhile auditor, who have expressed unmodified conclusion vide their review report dated August 07, 2025 whose review reports have been furnished to us and which have been relied upon by us for the purpose of our review of the statement. Our conclusion is not modified in respect of this matter.

**For Bilimoria Mehta & Co.**

Chartered Accountants

FRN: 101490W



**Aakash Mehta**

Partner

Membership no. 165824

UDIN: 25165824BMIIOI2650

Place of Signature: Mumbai

Date: November 06, 2025



**GENPHARMASEC LIMITED**  
CIN: L24231MH1992PLC323914  
**Statement of Standalone unaudited financial results for the Quarter and Half year ended September 30, 2025**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Half Year ended		Year ended
	30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024	31st March 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	3,156.37	1,211.32	576.95	4,367.68	1,107.24	3,296.36
II. Other Income	100.02	82.24	85.82	182.26	143.61	342.80
<b>III. Total Income (I + II)</b>	<b>3,256.39</b>	<b>1,293.55</b>	<b>662.77</b>	<b>4,549.94</b>	<b>1,250.85</b>	<b>3,639.16</b>
<b>IV. Expenses:</b>						
(a) Cost of materials consumed	-	-	-	-	-	-
(b) Purchase of Stock-in-Trade	3,977.54	1,122.56	561.09	5,100.10	1,150.08	3,000.72
(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(925.84)	(69.84)	(59.32)	(995.69)	(178.43)	33.76
(d) Employee benefit expense	18.82	21.19	14.02	40.01	31.31	66.81
(e) Financial costs	7.86	7.67	4.06	15.53	11.17	27.75
(f) Depreciation and amortization expense	4.49	4.31	4.26	8.80	4.75	13.31
(g) Other expenses	35.46	37.07	35.53	72.53	55.64	119.00
<b>V. Total Expenses</b>	<b>3,118.32</b>	<b>1,122.97</b>	<b>559.64</b>	<b>4,241.30</b>	<b>1,074.52</b>	<b>3,261.35</b>
<b>VI. Profit before tax (III - V)</b>	<b>138.06</b>	<b>170.58</b>	<b>103.13</b>	<b>308.65</b>	<b>176.33</b>	<b>377.81</b>
<b>Tax expense:</b>						
(1) Current tax	60.94	16.81	-	77.75	-	68.74
(2) Deferred Tax	(4.47)	(2.15)	(3.36)	(6.61)	(17.69)	29.03
(3) Prior Period Tax	-	-	-	-	-	-
<b>VII. Total Tax Expense</b>	<b>56.47</b>	<b>14.66</b>	<b>(3.36)</b>	<b>71.13</b>	<b>(17.69)</b>	<b>97.77</b>
<b>VIII. Profit for the period (VI-VII)</b>	<b>81.59</b>	<b>155.92</b>	<b>99.77</b>	<b>237.51</b>	<b>158.64</b>	<b>280.04</b>
<b>Other Comprehensive Income/(Loss)</b>						
(i) Items that will not be reclassified to Profit and Loss						
(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-	-	-
(b) Income tax effect on above	-	-	-	-	-	-
(c) Equity instrument through other comprehensive income	(18.07)	14.26	(15.18)	(3.81)	7.24	(81.81)
(d) Income tax effect on above	-	-	-	-	-	-
<b>IX. Total Other Comprehensive Income / (Loss)</b>	<b>(18.07)</b>	<b>14.26</b>	<b>(15.18)</b>	<b>(3.81)</b>	<b>7.24</b>	<b>(81.81)</b>
<b>X. Total Comprehensive Income/(Loss) for the year (VIII + IX)</b> (Comprising profit and other comprehensive income for the year)	<b>63.52</b>	<b>170.18</b>	<b>84.59</b>	<b>233.70</b>	<b>165.88</b>	<b>198.22</b>
<b>Paid up Equity Share Capital ( Face Value of Equity Share is Rs. 1/- each )</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>
<b>XI. Earning per equity share</b>						
(a) Basic	0.01	0.03	0.02	0.04	0.03	0.04
(b) Diluted	0.01	0.03	0.02	0.04	0.03	0.04

**Notes:**

- The above financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
- During the financial year, the Company reviewed its accounting policy relating to the classification and measurement of certain equity shares that were previously presented under Inventories. Upon a detailed evaluation of the nature and purpose of holding these shares, the management concluded that these instruments are held for investment purposes rather than for trading in the ordinary course of business. Accordingly, during the current year, the Company has reclassified such shares from Inventories to Financial Investments in accordance with the requirements of Ind AS 109 - Financial Instruments and Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. Consequently, these financial instruments are now measured at fair value through other comprehensive income (FVOCI) instead of being measured at the lower of cost and net realizable value under Ind AS 2 - Inventories. The change in accounting policy has been applied retrospectively, and the financial impact of this reclassification for the period ended September 30, 2025, is as follows:  
  - Decrease in Inventories: Rs. 89.32 Lakhs
  - Increase in Non-Current Investments: Rs. 87.69 Lakhs
  - Net Impact on Profit Before Tax: Nil
  - Net impact on total comprehensive income: Rs.(1.63) Lakhs
- The company is primarily engaged in one business segment in accordance with the requirement of Indian Accounting Standards (IND AS) 108 : Operating Segment. Accordingly, no separate segment information has been provided.
- The Financial result were reviewed by the Audit Committee and approved by the Board of directors at their meeting on November 06, 2025.
- The results for the quarter ended September 30, 2025 are the balancing figures between in respect of the half year ended results as on September 30, 2025 and the published unaudited financial results for the quarter ended June 30, 2025. Similarly, The results for the quarter ended September 30, 2024 are the balancing figures between in respect of the half year ended results as on September 30, 2024 and the published unaudited financial results for the quarter ended June 30, 2024.
- During the year ended March 31, 2024, the Company entered into a Share Purchase Agreement (SPA) and a Share Subscription-cum-Shareholders Agreement (SSSA) on September 19, 2023 with M/s. Derren Healthcare Private Limited and its promoters for acquiring a 70% stake. The acquisition was completed on July 25, 2025, and accordingly, Derren Healthcare Private Limited became a subsidiary of the Company in compliance with SEBI (LODR) Regulations, 2015, as amended from time to time.

For and on behalf of the Board of  
Genpharmasec Limited

*Sohan*  
Sohan Chaturvedi  
(Whole Time  
Director & CFO)  
DIN : 09629728



Place: Mumbai  
Date : November 06, 2025



**GENPHARMASEC LIMITED**  
**CIN: L24231MH1992PLC323914**  
**Statement of Standalone Assets and Liabilities**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)	As at March 31, 2024 (Audited)
<b>ASSETS</b>			
<b>1. Non-Current Assets</b>			
(a) Plant Property and Equipments	9.03	9.11	10.16
(b) Right to Use Assets	19.64	27.02	-
(c) Financial Assets			
(i) Non-Current Investment	2,200.11	2,083.76	1,909.72
(ii) Loans and Advances	2,562.60	2,896.46	1,207.22
(iii) Other Financial Assets	1,041.53	185.31	4.50
(d) Deferred Tax Assets (Net)	20.19	13.57	-
(e) Other Non Current Assets	0.23	0.33	42.60
	<b>5,853.33</b>	<b>5,215.57</b>	<b>3,174.21</b>
<b>2. Current Assets</b>			
(a) Inventories	1,720.12	724.43	758.19
(b) Financial Assets			
(i) Investments	-	-	168.39
(ii) Trade Receivable	2,474.71	1,338.61	909.99
(iii) Cash and Cash Equivalents	429.58	52.25	291.67
(iv) Bank Balances Other than above	0.95	462.12	1,566.20
(v) Loans and Advances	605.27	84.13	0.69
(vi) Other Financial Assets	21.67	9.81	32.22
(c) Current Tax Assets (net)	-	-	4.94
(d) Other Current Assets	191.18	22.49	140.98
	<b>5,443.48</b>	<b>2,693.83</b>	<b>3,873.25</b>
<b>TOTAL - ASSETS</b>	<b>11,296.81</b>	<b>7,909.40</b>	<b>7,047.46</b>
<b>EQUITY AND LIABILITIES</b>			
<b>I. Equity</b>			
(a) Equity Share Capital	5,537.20	5,537.20	5,537.20
(b) Other Equity	1,351.49	1,117.79	919.57
	<b>6,888.69</b>	<b>6,654.99</b>	<b>6,456.77</b>
<b>II. Liabilities</b>			
<b>1. Non-Current Liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	304.26	314.69	321.04
(ii) Lease Liabilities	6.93	13.95	-
(b) Provisions	-	-	-
	<b>311.19</b>	<b>328.64</b>	<b>321.04</b>
<b>2. Current Liabilities</b>			
(a) Financial Liabilities			
(i) Lease liabilities	14.58	14.62	-
(ii) Trade Payables			
a) Total outstanding dues of micro enterprises and small enterprises	14.22	16.64	11.73
b) Total outstanding dues of creditors other than micro enterprises	3,800.00	801.88	226.06
(iii) Others Financial liabilities	16.76	15.47	-
(b) Other Current Liabilities	127.17	17.66	31.86
(c) Current Tax Liabilities (Net)	124.20	59.49	-
	<b>4,096.94</b>	<b>925.76</b>	<b>269.65</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>11,296.81</b>	<b>7,909.40</b>	<b>7,047.46</b>

For and on Behalf of the Board of Directors of  
Genpharmasec Limited

*Sohan*

Sohan Chaturvedi  
(Whole Time Director &  
CFO)  
DIN : 09629728



Place: Mumbai  
Date : November 06, 2025



**GENPHARMASEC LIMITED**  
CIN: L24231MH1992PLC323914  
**Statement of Standalone Unaudited Cash Flow**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	For the period ended September 30, 2025 (Unaudited)	For the period ended September 30, 2024 (Unaudited)
<b>A) Cash Flow from Operating Activities</b>		
Net Profit Before Tax	308.65	176.33
Add : Adjustment for :		
Depreciation	8.61	4.75
Expected Credit Loss	25.66	20.24
Interest Income	(171.36)	(143.61)
Finance Cost	14.25	11.17
Other Provisions	-	7.66
Interest on lease liabilities	1.28	-
Dividend	(0.01)	-
<b>Operating Profit before Working Capital Changes</b>	<b>187.07</b>	<b>76.54</b>
Add : Adjustment for		
Inventories	(995.69)	(178.43)
Trade Receivables	(1,151.58)	332.33
Other Non Current & Current Financial Assets	(7.55)	(3.85)
Other Current Assets & Non Current Assets	(168.40)	60.23
Trade payables	2,995.70	231.35
Other Financial Liabilities	1.30	4.69
Other Current Liabilities	109.50	(31.86)
<b>Net Changes in Working Capital</b>	<b>783.29</b>	<b>414.46</b>
<b>Cash Generated from Operations</b>	<b>970.36</b>	<b>491.00</b>
Less : Direct Taxes Paid	(13.04)	(8.20)
<b>Net Cash Generated from Operating Activities</b>	<b>957.32</b>	<b>482.80</b>
<b>B) Cash Flow from Investing Activities</b>		
Purchase of Property, Plant & Equipment	(1.14)	(0.50)
Investments made	(120.16)	(89.70)
Fixed Asset Deposit created	(856.03)	(954.02)
Loans given	(48.56)	(1,055.64)
Receipt against loan given	0.42	-
Interest Received	17.33	156.35
Dividend Received	0.01	-
<b>Net Cash used in Investment Activities</b>	<b>(1,008.13)</b>	<b>(1,943.52)</b>
<b>C) Cash Flow from Financing Activities</b>		
Proceeds from Long term Borrowings	-	0.06
Repayment of Long term Borrowings	(10.44)	-
Payment of Lease liability	(8.34)	(4.67)
Loan Redeemed	-	(13.63)
Finance charges paid	(14.25)	(10.25)
<b>Net Cash generated/(used) in Financing Activities</b>	<b>(33.02)</b>	<b>(28.49)</b>
<b>Net Increase/ (Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(83.83)</b>	<b>(1,489.21)</b>
Add : Balance at the beginning of the year	514.37	1,857.86
<b>Cash and Cash Equivalents at the close of the year</b>	<b>430.54</b>	<b>368.65</b>

**Notes**


The cash flow statement is prepared using the indirect method set out in IND AS 7 - Statement of Cash Flow

Place: Mumbai

Date : November 06, 2025

For and on behalf of the Board of  
Genpharmasec Limited

*Sohan*  
Sohan Chaturvedi  
(Whole Time Director &  
CFO)  
DIN : 09629728





**Independent Auditor's Review Report on the Quarterly and Year to Date Consolidated Unaudited Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To,**  
**The Board of Directors of Genpharmasec Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results ('the Statement') of Genpharmasec Limited ('the Holding Company') and its Subsidiaries (the Holding Company and its Subsidiaries together referred to as the "the Group") for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 attached herewith being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities mentioned in Annexure I



5. Based on our review conducted and procedures performed above as stated in paragraph 3 and based on the consideration of the review reports of the other auditors referred to in paragraph 6 & 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of one subsidiary, whose unaudited interim financial results include total assets of Rs. 2,982.77 lakhs as at September 30, 2025, total revenue of Rs. 150.96 lakhs, total net loss after tax of Rs. 171.60 lakhs, total comprehensive loss of Rs. 171.60 lakhs from the date of acquisition to September 30, 2025; and net cash outflow of Rs. 23.68 lakhs from the date of acquisition to September 30, 2025, as considered in the Statement, which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of one of the subsidiaries which is located outside India have been prepared in accordance with accounting principles generally accepted in their respective countries. The Holding Company's management has converted the financial results of such subsidiary located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. The financial results and other financial information reflect total assets of Rs. 11.89 Lakhs as at September 30, 2025 and total revenue of Rs. Nil and Nil, total Net loss after tax of Rs. Nil and 0.08 Lakhs, total comprehensive loss of Rs. Nil and 0.08 Lakhs for the quarter ended September 30, 2025 and the period ended on that date respectively. Net cash inflow of Rs. 5.31 Lakhs for the period April 01, 2025 to September 30, 2025. We have reviewed these conversion adjustments made by the Holding Company's management.

The unaudited interim financial results and other unaudited financial information of the subsidiary have not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the subsidiary, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.




Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

**Other Matter**

8. The review of consolidated unaudited quarterly financial results for the period ended June 30, 2025, included in the Statement was carried out and reported by erstwhile auditor, who have expressed unmodified conclusion vide their review report dated August 07, 2025 whose review reports have been furnished to us and which have been relied upon by us for the purpose of our review of the statement. Our conclusion is not modified in respect of this matter.

**For Bilimoria Mehta & Co.**  
Chartered Accountants  
FRN: 101490W



**Aakash Mehta**  
Partner  
Membership no. 165824  
UDIN: 25165824BMII0J7615  
Place of Signature: Mumbai  
Date: November 06, 2025

**Annexure -1**

Sr. No	Particulars	Stake	Status
1	Clinigenome India Private Limited	99.99%	Subsidiary
2	Genpharmasec Middle East DMCC	52.00%	Subsidiary
3	Derren Healthcare Private Limited	70.00%	Subsidiary





**GENPHARMASEC LIMITED**

CIN: L24231MH1992PLC323914

**Statement of Consolidated unaudited financial results for the Quarter and Half year ended September 30, 2025**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended		Half Year ended		Year ended	
	30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024	31st March 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>I. Revenue from operations</b>	3,263.71	1,204.32	603.31	4,468.04	1,122.80	3,372.18
<b>II. Other Income</b>	46.48	69.48	74.74	115.95	131.34	306.22
<b>III. Total Income (I + II)</b>	<b>3,310.19</b>	<b>1,273.80</b>	<b>678.04</b>	<b>4,583.99</b>	<b>1,254.14</b>	<b>3,678.40</b>
<b>IV. Expenses:</b>						
(a) Cost of materials consumed	88.77	12.86	11.10	101.63	47.01	87.21
(b) Purchase of Stock-in-Trade	3,977.54	1,122.56	561.09	5,100.10	1,135.63	2,960.22
(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(1,028.69)	(104.59)	(48.89)	(1,133.28)	(200.98)	27.74
(d) Employee benefit expense	119.72	34.96	19.32	154.68	36.91	99.91
(e) Financial costs	22.52	12.26	6.95	34.78	17.15	43.48
(f) Depreciation and amortization expense	56.21	26.59	30.03	82.80	45.63	81.15
(g) Other expenses	153.72	44.55	47.96	198.27	71.36	157.52
<b>V. Total Expenses</b>	<b>3,389.79</b>	<b>1,149.19</b>	<b>627.57</b>	<b>4,538.98</b>	<b>1,152.71</b>	<b>3,457.22</b>
<b>VI. Profit before tax (III - V)</b>	<b>(79.60)</b>	<b>124.61</b>	<b>50.47</b>	<b>45.01</b>	<b>101.44</b>	<b>221.18</b>
<b>Tax expense:</b>						
(1) Current tax	56.88	16.81	-	73.69	-	68.74
(2) Deferred Tax	(18.86)	(13.72)	19.89	(32.58)	1.78	(3.84)
(3) Prior Period Tax	-	-	-	-	-	-
<b>VII. Total Tax Expense</b>	<b>38.02</b>	<b>3.09</b>	<b>19.89</b>	<b>41.11</b>	<b>1.78</b>	<b>64.90</b>
<b>VIII. Profit for the period (VI-VII)</b>	<b>(117.62)</b>	<b>121.52</b>	<b>70.37</b>	<b>3.90</b>	<b>103.22</b>	<b>156.28</b>
<b>Other Comprehensive Income/(Loss)</b>						
(i) Items that will not be reclassified to Profit and Loss						
(a) Re-measurement gains/(losses) on defined benefit plans	-	-	-	-	-	-
(b) Income tax effect on above	-	-	-	-	-	-
(c) Equity instrument through other comprehensive income	(18.07)	14.26	(15.18)	3.81	7.24	(81.81)
(d) Income tax effect on above	-	-	-	-	-	-
<b>IX. Total Other Comprehensive Income / (Loss)</b>	<b>(18.07)</b>	<b>14.26</b>	<b>(15.18)</b>	<b>(3.81)</b>	<b>7.24</b>	<b>(81.81)</b>
<b>X. Total Comprehensive Income/(Loss) for the year (VIII + IX)</b>	<b>(135.69)</b>	<b>135.78</b>	<b>55.18</b>	<b>0.09</b>	<b>110.46</b>	<b>74.47</b>
<b>(Comprising profit and other comprehensive income for the year)</b>						
<b>Profit/(Loss) Attributable to Parent</b>	<b>(84.17)</b>	<b>135.79</b>	<b>(2.52)</b>	<b>51.62</b>	<b>(2.74)</b>	<b>76.79</b>
<b>Profit/(Loss) Attributable to Non-Controlling Interest</b>	<b>(51.52)</b>	<b>(0.00)</b>	<b>57.70</b>	<b>(51.52)</b>	<b>113.21</b>	<b>(2.32)</b>
<b>Paid up Equity Share Capital ( Face Value of Equity Share is Rs. 1/- each )</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>	<b>5,537.20</b>
<b>Other Equity</b>						<b>990.77</b>
<b>XI. Earning per equity share</b>						
(a) Basic	(0.02)	0.02	0.01	0.00	0.02	0.02
(b) Diluted	(0.02)	0.02	0.01	0.00	0.02	0.02


**Notes:**

- The above financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.
- During the financial year, the Holding Company reviewed its accounting policy relating to the classification and measurement of certain equity shares that were previously presented under Inventories. Upon a detailed evaluation of the nature and purpose of holding these shares, the management concluded that these instruments are held for investment purposes rather than for trading in the ordinary course of business. Accordingly, during the current year, the Holding Company has reclassified such shares from Inventories to Financial Investments in accordance with the requirements of Ind AS 109 - Financial Instruments and Ind AS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. Consequently, these financial instruments are now measured at fair value through other comprehensive income (FVOCI) instead of being measured at the lower of cost and net realizable value under Ind AS 2 - Inventories. The change in accounting policy has been applied retrospectively, and the financial impact of this reclassification for the period ended September 30, 2025, is as follows:  
 • Decrease in Inventories: Rs. 89.32 Lakhs  
 • Increase in Non-Current Investments: Rs. 87.69 Lakhs  
 • Net Impact on Profit Before Tax: Nil  
 • Net impact on total comprehensive income: Rs. (1.63) Lakhs
- The Consolidated Financial result were reviewed by the Audit Committee and approved by the Board of directors at their meeting on November 06, 2025.
- Segment Reporting has been annexed in Annexure I.
- The results for the quarter ended September 30, 2025 are the balancing figures between in respect of the half year ended results as on September 30, 2025 and the published unaudited financial results for the quarter ended June 30, 2025. Similarly, the results for the quarter ended September 30, 2024 are the balancing figures between in respect of the half year ended results as on September 30, 2024 and the published unaudited financial results for the quarter ended June 30, 2024.
- During the year ended March 31, 2024, the Company entered into a Share Purchase Agreement (SPA) and a Share Subscription-cum-Shareholders Agreement (SSSA) on September 19, 2023 with M/s. Derren Healthcare Private Limited and its promoters for acquiring a 70% stake. The acquisition was completed on July 25, 2025, and accordingly, Derren Healthcare Private Limited became a subsidiary of the Company in compliance with SEBI (LODR) Regulations, 2015, as amended from time to time.

For and on behalf of the Board of  
Genpharmasec Limited

*Sohan*

**Sohan Chaturvedi**  
(Whole Time  
Director & CFO)  
DIN : 09629728



Place: Mumbai  
Date: November 06, 2025



**GENPHARMASEC LIMITED**  
CIN: L24231MH1992PLC323914  
**Statement of Consolidated Assets and Liabilities**  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	As at September 30, 2025 (Unaudited)	As at March 31, 2025 (Audited)	As at March 31, 2024 (Audited)
<b>ASSETS</b>			
<b>1. Non-Current Assets</b>			
(a) Plant Property and Equipments	2,234.08	555.79	10.16
(b) Right to Use Assets	173.01	202.54	73.74
(c) Intangible Assets	1.34	-	-
(d) Goodwill	1,811.79	-	-
(e) Financial Assets			
(i) Non - Current Investment	205.24	1,973.00	1,889.98
(ii) Loans and Advances	628.00	2,312.94	1,124.72
(iii) Other Financial Assets	1,073.91	210.14	4.50
(f) Other Non Current Assets	441.71	46.18	-
(g) Deferred Tax Assets (Net)	212.97	46.44	42.60
(h) Non Current Tax Assets (Net)	9.74	-	-
	<b>6,791.81</b>	<b>5,347.03</b>	<b>3,145.70</b>
<b>2. Current Assets</b>			
(a) Inventories	1,958.50	730.45	758.19
(b) Financial Assets			
(i) Investments	-	-	168.39
(ii) Trade Receivable	2,454.29	1,359.63	909.99
(iii) Cash and Cash Equivalents	502.64	65.02	316.96
(iv) Bank Balances Other than above	1.20	462.12	1,566.20
(v) Loans and Advances	0.60	-	0.69
(vi) Other Financial Assets	21.87	0.90	-
(c) Current Tax Assets (net)	12.33	-	4.94
(d) Other Current Assets	656.26	24.07	241.51
	<b>5,607.69</b>	<b>2,642.19</b>	<b>3,966.85</b>
<b>TOTAL - ASSETS</b>	<b>12,399.50</b>	<b>7,989.22</b>	<b>7,112.56</b>
<b>EQUITY AND LIABILITIES</b>			
<b>I. Equity</b>			
(a) Equity Share Capital	5,537.20	5,537.20	5,537.20
(b) Other Equity	1,030.72	979.11	902.34
(c) Non- Controlling Interest	(9.18)	11.65	13.95
	<b>6,558.74</b>	<b>6,527.95</b>	<b>6,453.49</b>
<b>II. Liabilities</b>			
<b>1. Non-current Liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings	738.49	314.69	321.04
(ii) Lease Liabilities	136.67	161.97	67.83
(iii) Provisions	7.23	1.04	-
	<b>882.39</b>	<b>477.70</b>	<b>388.87</b>
<b>2. Current liabilities</b>			
(a) Financial Liabilities			
(i) Trade Payables			
a) Total outstanding dues of micro enterprises and small enterprises	30.95	16.64	11.73
b) Total outstanding dues of creditors other than micro enterprises	3,962.45	809.25	226.16
(ii) Borrowings	174.09	-	-
(iii) Lease liabilities	52.02	51.79	-
(iv) Others Financial liabilities	449.56	15.46	-
(b) Other Current Liabilities	164.22	34.00	32.31
(c) Current Tax Liabilities(net)	-	56.41	-
(d) Provisions	125.07	0.00	-
	<b>4,958.37</b>	<b>983.56</b>	<b>270.20</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>12,399.50</b>	<b>7,989.22</b>	<b>7,112.56</b>

For and on Behalf of the Board of Directors of  
Genpharmasec Limited

*Sohan*

Sohan Chaturvedi  
(Whole Time Director &  
CFO)  
DIN : 09629728



Place: Mumbai  
Date: November 06, 2025



**GENPHARMASEC LIMITED**

**CIN: L24231MH1992PLC323914**

**Statement of Consolidated Unaudited Cash Flow**

(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars		For the period ended September 30, 2025 (Unaudited)	For the period ended September 30, 2024 (Unaudited)
<b>A)</b>	<b><u>Cash Flow from Operating Activities</u></b>		
	Net Profit Before Tax	45.01	101.44
	Add : Adjustment for :		
	Depreciation	81.94	45.63
	Expected Credit Loss	25.66	20.24
	Interest Income	(105.05)	(131.34)
	Other Provisions	6.19	7.66
	Finance Cost	24.49	17.15
	Interest on lease liabilities	10.17	-
	Dividend	(0.01)	-
	<b>Operating Profit before Working Capital Changes</b>	<b>88.40</b>	<b>60.78</b>
	Add : Adjustment for		
	Inventories	(1,142.77)	(200.98)
	Trade Receivables	(1,007.89)	334.99
	Other Non Current & Current Financial Assets	86.59	(11.19)
	Other Current Assets	(187.86)	126.30
	Other Non Current Assets	41.72	(84.03)
	Trade payables	3,101.70	245.55
	Other Financial Liabilities	199.44	6.74
	Other Current Liabilities	85.69	(32.31)
	<b>Net Changes in Working Capital</b>	<b>1,176.61</b>	<b>385.08</b>
	<b>Cash Generated from Operations</b>	<b>1,265.01</b>	<b>445.86</b>
	Less : Direct Taxes Paid	(147.21)	(9.02)
	<b>Net Cash Generated from Operating Activities</b>	<b>1,117.80</b>	<b>436.85</b>
<b>B)</b>	<b><u>Cash Flow from Investing Activities</u></b>		
	Purchase of Fixed Assets	(54.46)	(410.38)
	Investments made	(119.45)	(26.99)
	Fixed Asset Deposit created	(857.03)	(954.02)
	Loans given	1,673.75	(592.12)
	Receipt against loan given	0.42	-
	Interest Received	21.84	143.85
	Dividend Received	0.01	-
	<b>Net Cash used in Investment Activities</b>	<b>665.08</b>	<b>(1,839.67)</b>
<b>C)</b>	<b><u>Cash Flow from Financing Activities</u></b>		
	Repayment of long term borrowing	(1,815.58)	0.06
	Payment of Lease liability	(35.24)	(88.72)
	Finance charges paid	(24.49)	(9.71)
	<b>Net Cash generated/(used ) in Financing Activities</b>	<b>(1,875.31)</b>	<b>(98.37)</b>
	<b>Net Increase/ (Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(92.44)</b>	<b>(1,501.19)</b>
	<b>Cash &amp; cash equivalents acquired pursuant to acquisition of subsidiary</b>	<b>69.14</b>	
	Add : Balance at the beginning of the year	527.14	1,883.16
	<b>Cash and Cash Equivalents at the close of the year</b>	<b>503.84</b>	<b>381.97</b>

**Notes**


The cash flow statement is prepared using the indirect method set out in IND AS 7 - Statement of Cash Flow

For and on behalf of the Board of  
Genpharmasec Limited

*Sohan*

**Sohan Chaturvedi**  
(Whole Time Director &  
CFO)

DIN : 09629728



Place: Mumbai

Date: November 06, 2025



**GENPHARMASEC LIMITED**  
CIN: L24231MH1992PLC323914  
"ANNEXURE - I"

Statement of Consolidated unaudited Segment-wise Revenue, Results, Assets and Liabilities for the Quarter and Half Year ended September 30, 2025  
(All amounts in Indian Rupees Lakhs, except as otherwise stated)

Particulars	Quarter Ended			Half Year Ended	Half Year Ended	Year Ended
	30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024	31st March 2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>Segment Revenue</b>						
Pharmaceuticals	3,071.70	1,167.09	576.95	4,238.79	1,092.79	3,255.86
Laboratory Testing	41.05	37.24	26.35	78.29	30.01	116.32
Derren	150.96	-	-	150.96	-	-
<b>Total</b>	<b>3,263.71</b>	<b>1,204.32</b>	<b>603.31</b>	<b>4,468.04</b>	<b>1,122.80</b>	<b>3,372.18</b>
<b>Segment Results (Profit before tax and interest)</b>						
Pharmaceuticals	145.93	178.25	95.84	324.18	174.99	405.56
Laboratory Testing	(37.57)	(41.38)	(33.83)	(78.96)	(51.74)	(136.09)
Derren	(165.35)	-	-	(165.35)	-	-
Unallocable	(0.08)	-	(4.59)	(0.08)	(4.66)	(4.81)
<b>Total</b>	<b>(57.08)</b>	<b>136.87</b>	<b>57.43</b>	<b>79.79</b>	<b>118.59</b>	<b>264.67</b>
<b>Less</b>						
(i) Unallocated Finance Cost	(22.52)	(12.26)	-0.00	(34.78)	(17.15)	(43.48)
(ii) Other unallocable expenditure net of unallocable income	-	-	-	-	-	-
(iii) Inter Segment Eliminations	-	-	-	-	-	-
<b>Profit Before Tax</b>	<b>(79.60)</b>	<b>124.61</b>	<b>50.47</b>	<b>45.01</b>	<b>101.44</b>	<b>221.18</b>
<b>Segment Assets</b>						
Pharmaceuticals	-0.00	0.00	-	-0.00	-	-
Laboratory Testing	8,445.12	2,023.11	1,874.45	8,445.12	1,874.45	2,329.91
Derren	959.72	884.47	741.19	959.72	741.19	880.59
Un-Allocated	2,982.77	-	-	2,982.77	-	-
<b>Total</b>	<b>12,399.50</b>	<b>8,276.32</b>	<b>7,538.36</b>	<b>12,399.50</b>	<b>7,538.36</b>	<b>7,989.22</b>
<b>Segment Liabilities</b>						
Pharmaceuticals	4,408.13	968.78	516.53	4,408.13	516.53	1,365.18
Laboratory Testing	820.97	211.08	140.41	820.97	140.41	96.09
Derren	606.26	-	-	606.26	-	-
Un-Allocated	5.41	432.71	330.31	5.41	330.31	-
<b>Total</b>	<b>5,840.76</b>	<b>1,612.57</b>	<b>987.25</b>	<b>5,840.74</b>	<b>987.25</b>	<b>1,461.27</b>

The company has reported segment information as per the Indian Accounting Standard 108 "Operating Segments" (IND AS 108).

For and on behalf of the Board of  
Genpharmasec Limited

*Sohan*

Sohan Chaturvedi  
(Whole Time Director &  
CFO)  
DIN : 09629728



Place: Mumbai  
Date: November 06, 2025